Page 48 - 2020_07-Haematologica-web

P.A. Egan et al.
Escoboza JR, Bolanos-Meade J. Rapid com- plete response using intrathecal rituximab in a patient with leptomeningeal lymphomato- sis due to mantle cell lymphoma. Anticancer Drugs. 2008;19(9):917-920.
57. Tsang RW, Campbell BA, Goda JS, et al. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018;101(4):794- 808.
58. Riley JM, Russo JK, Shipp A, Alsharif M, Jenrette JM. Central nervous system myelo- matosis with optic neuropathy and intramedullary spinal cord compression responding to radiation therapy. Jpn J Radiol. 2011;29(7):513-516.
59. Kauffmann G, Buerki RA, Lukas RV, Gondi V, Chmura SJ. Case Report of Bone Marrow- Sparing Proton Therapy Craniospinal Irradiation for Central Nervous System Myelomatosis. Cureus. 2017;9(11):e1885.
60. Lee SE, Kim JH, Jeon YW, et al. Impact of extramedullary plasmacytomas on out- comes according to treatment approach in newly diagnosed symptomatic multiple myeloma. Ann Hematol. 2015;94(3):445- 452.
61. Wu P, Davies FE, Boyd K, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma. 2009;50(2):230-235.
62. Vercruyssen M, El Hachem G, Maerevoet M. The Daratumumab crosses the blood brain barrier. Clin Lymphoma Myeloma Leuk. 2018;18:S289.
63. Elhassadi E, Murphy M, Hacking D, Farrell M. Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab. Clin Case Rep. 2018;6 (4):723-728.
64. Martin T, Strickland S, Glenn M, et al. Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. Blood Cancer J. 2019;9(4):41.
65. Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low- dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple
Involvement. Oncologist. 2020;25(2):112- multicentre, open-label, phase 3 study. 118.
myeloma (ICARIA-MM): a randomised,
Lancet. 2019;394(10214):2096-2107.
66. Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N
Engl J Med. 2018;379(19):1811-1822.
67. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J
Med. 2015;373(7):621-631.
68. Pistofidis R, Ghobrial I. Targeting a
Myeloma Translocation for the First Time: The t(11;14) Journey. The Hematologist. 2018;15(4).
69. Campo E, Cymbalista F, Ghia P, et al. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical impli- cations of improved diagnostics. Haematologica. 2018;103(12):1956-1968.
70. Reda G, Cassin R, Dovrtelova G, et al. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. Haematologica. 2019;104(5): e222-e223.
71. Ruiz-Heredia Y, Sanchez-Vega B, Onecha E, et al. Mutational screening of newly diag- nosed multiple myeloma patients by deep targeted sequencing. Haematologica. 2018;103(11):e544-e548.
72. Kortum KM, Mai EK, Hanafiah NH, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016;128(9):1226-1233.
73. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373(8):726-736.
74. Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863-873.
75. Da Via MC, Solimando AG, Garitano- Trojaola A, et al. CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System
76. Thaler FS, Laurent SA, Huber M, et al. Soluble TACI and soluble BCMA as bio- markers in primary central nervous system lymphoma. Neuro Oncol. 2017;19(12):1618- 1627.
77. Benjamin R. Advances in off-the-shelf CAR T-cell therapy. Clin Adv Hematol Oncol. 2019;17(3):155-157.
78. Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985-1005.
79. Sanchez E, Li M, Kitto A, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158 (6):727-738.
80. Ghermezi M, Li M, Vardanyan S, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017; 102(4):785-795.
81. Bujarski S, Soof C, Li M, et al. Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 Trial Evaluating Ruxolitinib, Lenalidomide and Methylprednisolone. Blood. 2018;132: 1894.
82. Marron TU, Ramanathan L, Chari A. Diagnostic utility of measuring free light chains in the cerebrospinal fluid of patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2015;15(6):e127-131.
83. Qu X, Chen L, Qiu H, et al. Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberra- tion and novel agents resistance. Biomed Res Int. 2015;2015:787809.
84. Gozzetti A, Cerase A, Bocchia M. Central nervous system multiple myeloma. Ann Hematol. 2016;95(3):519-520.
85. Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexametha- sone in myeloma refractory to both borte- zomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011;118(11):2970-2975.
1790
haematologica | 2020; 105(7)